StreetAlpha.app
Home › Stocks › BMRN

Biomarin Pharmaceutical Inc (BMRN)

Healthcare
$58.51
▲ +0.90%
LAST CLOSE · NOV 17

BioMarin Pharmaceutical develops and sells medicines for people with rare genetic diseases. It last closed at $58.51 on Nov 17, up 0.90% on the day. BMRN last reported earnings on Mon, Nov 2, 2026. The average 12-month price target from 9 analysts is $89.56 (+53.1% from the last close), with a high of $114.00 and a low of $60.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (7 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in BMRN, 50% of them bullish and 50% bearish. In the past 30 days there were 2 dark pool prints totaling $2.7M, the largest $1.7M.

AI Auto Pilots
Is BMRN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.7B
+18.1% vs a year ago
Net income
−$19.1M
−103.7% vs a year ago
EPS (diluted)
−$0.10
−103.7% vs a year ago
Free cash flow
$557.9M
15.3% margin
Valuation
Market cap
$11.3B
193.7M shares
P/E
–
No P/E while losing money
Price to sales
3.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$736.0M
At Sep 30
Debt
$4.2B
At Sep 30
Shareholder equity
$6.3B
Shares outstanding
193.7M
At Oct 26
CEOJean Jacques Bienaime
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.8B$1.8BFY2021FY2022: $2.1B$2.1BFY2022FY2023: $2.4B$2.4BFY2023FY2024: $2.9B$2.9BFY2024FY2025: $3.2B$3.2BFY2025

From BMRN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Last report
Nov 2
2026 · After the close (AMC)
Reported EPS
$0.02
vs -$0.30 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±6.5%
Priced in before that report
Analyst consensus
Strong Buy
Based on 9 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
9firms
7 Buy2 Hold0 Sell
Each firm's latest rating on BMRN in the past 90 days
Average 12-month target
$89.56
▲ 53.1% upside

Based on 9 analysts who set a price target on BMRN in the past 90 days. The average target is $89.56, with a high of $114.00 and a low of $60.00, compared with the last close of $58.51.

Low $60.00Avg $89.56High $114.00
Blue marker: last close $58.51
Highest target$114.00
Average target$89.56
Lowest target$60.00
Latest rating changes
Morgan StanleyTarget lowered
Nov 13Buy$122 → $103
JP MorganTarget lowered
Nov 4Buy$87 → $86
OppenheimerTarget lowered
Nov 3Buy$97 → $94
RBC CapitalTarget lowered
Nov 3Hold$62 → $60
StifelMaintained
Nov 3Hold$66
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget loweredBuy$122 → $103
Nov 4JP MorganTarget loweredBuy$87 → $86
Nov 3OppenheimerTarget loweredBuy$97 → $94
Nov 3RBC CapitalTarget loweredHold$62 → $60
Nov 3StifelMaintainedHold$66
Loading…

Technical Analysis

BMRN · as of the Nov 17 close · updated after every close
Turning up

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is strong (RSI 55). The nearest support is the 200 day average at $58.47, and the nearest resistance the 50 day average at $58.56.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityHigh, 3.0%/day
Key levels
$70.9852 week high+21.3%
$60.63100 day average+3.6%
$59.50Swing high (Nov 2)+1.7%
$59.00Pivot R1+0.8%
$58.5650 day average+0.1%
$58.51Last close
$58.47200 day average−0.1%
$58.16Pivot−0.6%
$57.77Swing low (Jul 14)−1.3%
$57.68Pivot S1−1.4%
$56.8220 day average−2.9%
$49.2652 week low−15.8%
Indicators
RSI (14)55.05Middle of its rangeNeutral
MACD-0.01Above its signal lineBullish
Stochastic78.8Middle of its rangeNeutral
ADX (14)16.9No clear trend
Williams %R-13.2Oversold below −80, overbought above −20Overbought
CCI (20)113.5Oversold below −100, overbought above 100Overbought
Rate of change+5.1%Change over 10 sessionsBullish
ATR (14)$1.78Typical daily range, 3.0% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for BMRN

What happened before

See how BMRN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BMRN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BMRN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Oct 20 – Nov 3
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.7M
Largest print
$1.7M
Loading…

BMRN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●282 buying vs 256 selling
  • ▼Held by funds -6.6 pts
  • ●Funds holding +3
  • ●Superinvestors: 3 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding582579+0.5%
In funds' top 101714+21.4%
Held by funds100.0%106.6%−6.6 pts
New / increased81 / 20183 / 205−2.1%
Reduced / sold out184 / 72196 / 82−7.9%
Put/call ratio0.440.35+23.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BMRN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMRN is in one of them and how their past BMRN trades turned out.

BMRN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BMRN in an article yet. Here's the latest on the wider market.

BMRN Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Apr 17
Who traded BMRN · since 2018
Latest 5 filings of 18
$1K – $15KTraded Mar 6, 2023Filed Apr 17, 2023
$1K – $15KTraded Mar 14, 2023Filed Apr 7, 2023
$1K – $15KTraded Dec 6, 2022Filed Jan 3, 2023
$1K – $15KTraded May 10, 2022Filed Jun 10, 2022
$1K – $15KTraded Oct 18, 2021Filed Nov 15, 2021
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KMar 6, 2023Apr 17, 202342 d
Ro KhannaD · CASell$1K – $15KMar 14, 2023Apr 7, 202324 d
Ro KhannaD · CABuy$1K – $15KDec 6, 2022Jan 3, 202328 d
Ro KhannaD · CASell$1K – $15KMay 10, 2022Jun 10, 202231 d
Josh GottheimerD · NJSell$1K – $15KOct 18, 2021Nov 15, 202128 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Biomarin Pharmaceutical

BioMarin Pharmaceutical develops and sells medicines for people with rare genetic diseases. Its products include VOXZOGO, a treatment for achondroplasia, the most common form of short stature caused by a genetic condition, and several enzyme therapies for conditions such as mucopolysaccharidosis and phenylketonuria. The company is based in California, and its customers are patients and the specialists who prescribe its treatments.

Headquarters
Novato, CA
Founded
1997